anti B7-H3 CAR T-cell therapy (Fuzhou Tcelltech Biotechnology)

N/A

Report date: 2025/06/11 11:06:59

Base Information

Drug Nameanti B7-H3 CAR T-cell therapy (Fuzhou Tcelltech Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD276 antigen modulatorsT lymphocytes stimulantsImmunostimulants
TargetsCD276 antigen
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCelltech
China Registration ClassN/A

Develop Information

Active CompaniesCelltech
Inactive CompaniesN/A
Active IndicationsGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A